Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07389473 · ClinicalTrials.gov registry record

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

A clinical trial of ADHD and Mood Disorders, sponsored by Gaize.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT07389473 is a study of ADHD and Mood Disorders that is actively recruiting participants, run by Gaize. The registered enrollment target is 50 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07389473, a study of ADHD and Mood Disorders, is actively recruiting participants, sponsored by Gaize.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.

Interventions

  • DRUG Prescription Psychotropic Medications

Study Locations (1)

Pennsylvania

  • Gaize - Philadelphia

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-04-17
Est. Completion 2028-08

Sponsor

Gaize

2 total trials

What the Registry Record Tells You About NCT07389473

The ClinicalTrials.gov registry entry for NCT07389473 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (74% lower). The listed sponsor is Gaize, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which Prescription Psychotropic Medications is the first listed.

NCT07389473 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07389473 about?

NCT07389473 is a clinical study titled "Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device". The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.

What is the current status of trial NCT07389473?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-04-17. Estimated completion is 2028-08.

What conditions does trial NCT07389473 study?

This clinical trial studies the following conditions: ADHD, Mood Disorders, Depression Disorders, Bipolar Disorder (BPD), Anxiety Disorder Generalized.

What interventions are being tested in trial NCT07389473?

The interventions under investigation include: Prescription Psychotropic Medications (DRUG).

Who is sponsoring clinical trial NCT07389473?

This trial is sponsored by Gaize, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07389473 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.